Last reviewed · How we verify

NCT06341166: SCIMITAR

Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse

Recruiting now Last updated 3 February 2026
What this trial tests

trial in Mitral Valve Prolapse in 300 participants. Currently enrolling.

Timeline
19 June 2023
Primary endpoint
19 June 2026
19 June 2026

Quick facts

Lead sponsorCentro Cardiologico Monzino
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment300
Start date19 June 2023
Primary completion19 June 2026
Estimated completion19 June 2026
Sites1 location across Italy

Conditions studied

Sponsor

Centro Cardiologico Monzino — full company profile →

Who can join

18 and older, any sex, with Mitral Valve Prolapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mitral Valve Prolapse

Currently open trials in the same condition.

Other Centro Cardiologico Monzino trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06341166.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing